logo-loader

Gryphon Minerals new COO to lead Banfora through DFS to development

Published: 19:23 23 Apr 2012 EDT

no_picture_pai

Gryphon Minerals (ASX: GRY) non-executive director Steven Zaninovich has stepped up to the new role of chief operating officer to lead the development of the company’s Banfora Gold Project in Burkina Faso.

Zaninovich’s main focus with Gryphon will be to lead the successful completion of the Definitive Feasibility Study and the development and construction of the company’s Banfora Gold Project.

Banfora has already reached the 2 million gold ounce milestone, hosting 29 million tonnes at 2.1 grams per tonne (g/t), of which the majority is less than 100 metres deep - while remaining open.

Zaninovich has experience in the development of major gold projects in West Africa, with his most recent role being project director for Newmont Mining Corporation (NYSE: NEM), leading the development and construction of the $1 billion, 7 million ounce Akyem Gold Project in Ghana.

Other experience in West Africa includes Gold Fields’ (NYSE: GFI) Tarkwa Phase IV project, Ashanti Goldfields’ Bibiani Gold Mine, Redback’s Chirano Gold Mine, Ranger Minerals’ Damang Mine Expansion and Resolute Mining’s (ASX: RSG) Obatan Gold mine.

Zaninovich will step down as non-executive director of Gryphon to focus on his new role with the company.

Gryphon managing director Steve Parsons said Zaninovich was ideally placed for the role with experience in the area and in the company.

“Steven’s hands on operational experience, project development leadership and considerable recent West African gold experience will be invaluable as we move forward in the development of the Banfora Gold Project,” Parsons said.

“Steven will assume direct responsibility for driving the DFS through to completion and then overseeing the development, construction and commissioning, and production at Banfora.”



Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 31 minutes ago